<DOC>
	<DOC>NCT00569374</DOC>
	<brief_summary>This 7 week, open-label pilot clinical trial will examine the safety and tolerability of modafinil up to 400mg/day as a potential treatment to reduce methamphetamine use in methamphetamine-dependent volunteers.</brief_summary>
	<brief_title>Safety and Tolerability of Modafinil for Methamphetamine Dependence</brief_title>
	<detailed_description />
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Methamphetamine</mesh_term>
	<criteria>1865 years old not currently enrolled in a treatment program subjects must have a history of methamphetamine use with recent use confirmed by a positive urine toxicology screen for amphetamines during the month prior to study entry subjects must meet DSMIV criteria for amphetamine dependence as assessed by the substance abuse section of the Structured Clinical Interview for DSMIV (SCID) women of childbearing age must have a negative pregnancy test to enroll in this study, agree to monthly pregnancy testing, and agree to use appropriate forms of birth control for the duration of the study current diagnosis of alcohol, opiate, or sedative physical dependence ill health (e.g., major cardiovascular, renal, endocrine, hepatic disorder) history of schizophrenia, or bipolar type I disorder present or recent use of overthecounter or prescription psychoactive drug or drug(s) that would be expected to have major interaction with drug to be tested medical contraindication to receiving study medications (e.g., allergy to modafinil, treatment with cyclosporine, clomipramine, or desipramine) Current suicidality or psychosis liver function tests (i.e., liver enzymes) greater than three times normal levels pregnancy or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>